Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 36,500 | |||
5 mg | 在庫あり | ¥ 91,500 | |||
10 mg | 在庫あり | ¥ 135,500 | |||
25 mg | 在庫あり | ¥ 217,000 | |||
50 mg | 在庫あり | ¥ 294,000 | |||
100 mg | 在庫あり | ¥ 397,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 105,500 |
説明 | GNF2133 is an effective and selective inhibitor of DYRK1A with IC50s of 6.2 nM. GNF2133 can be used in studies about type 1 diabetes. |
In vitro | GNF2133 has an IC50 of >50 µM for GSK3β. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion[1]. |
In vivo | In Diphtheria toxin A (RIP-DTA) mice, GNF2133 (3, 10, 30 mg/kg) significantly improves glucose disposal capacity and increased insulin secretion. In CD-1 mice, GNF2133 (30 mg/kg; p.o.) shows moderate plasma exposure and good oral absorption with oral bioavailability of 22.3%[1]. In Wistar Han rat, GNF2133 (30 mg/kg; p.o.) increases in cell proliferation marker Ki67 and insulin and reduces cyclin D1 levels and overall cell density[1]. |
分子量 | 434.53 |
分子式 | C24H30N6O2 |
CAS No. | 2561414-56-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4.5 mg/mL (10.36 mM), Sonication and heating to 60℃ are recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GNF2133 2561414-56-8 Cell Cycle/Checkpoint Tyrosine Kinase/Adaptors DYRK β-cell RIP-DTA mice Inhibitor insulin secretion inhibit Dual specificity tyrosine regulated kinase glucose disposal Dual specificity tyrosine phosphorylation regulated kinase GNF-2133 CD-1 mice GNF 2133 orally active inhibitor